LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday that the European Commission has approved Strimvelis, the stem-cell gene therapy aimed at treating patients with a rare immunodeficiency disease called ADA-SCID.

The healthcare company said Strimvelis is indicated for the treatment of patients with ADA-SCID for whom no suitable human donor is available.

The marketing-authorization decision was based on data collected from 18 children treated with Strimvelis, the company said.

Shares at 1500 GMT were down 4 pence, or 0.3%, at 1453 pence, valuing the company at 70.78 billion pounds ($104 billion).

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

May 27, 2016 11:44 ET (15:44 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Gsk Charts.
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Gsk Charts.